Pharmacy students' knowledge of black box warnings

American Journal of Pharmaceutical Education

Volumn 74, Issue 1, 2010, Pages 5-

  Moeller, Karen E ^a,b   Shireman, Theresa I ^b   Generali, Joyce ^a,b   Rigler, Sally ^b   Mayorga, Angela ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Adverse drug effects; Black box warning; Package insert; Pharmacy students; Product label

Indexed keywords

DRUG;

ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG LABELING; EDUCATION; HUMAN; PHARMACY STUDENT; PROFESSIONAL COMPETENCE; STANDARD;

CROSS-SECTIONAL STUDIES; DRUG LABELING; EDUCATION, PHARMACY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROFESSIONAL COMPETENCE; STUDENTS, PHARMACY;

EID: 77649087915     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj740105     Document Type: Article

References (12)

1. 21 Code of Federal Regulations paragraph 201.57(e) (2000).
2. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53(3):403-411.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220.
4. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Safety. 2006;15:369-386.
5. Generali JA. Black box drug list. www.formularyproductions.com/blackbox. Accessed January 12, 2010.
6. Top 200 brand drugs by retail dollars in 2007. Drug Topics. March 10,2008. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/102008/500221/article.pdf. Accessed January 12, 2010.
7. Top 200 generic drugs by retail dollars in 2007. Drug Topics. March 10, 2008. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/102008/500218/article.pdf. Accessed January 12, 2010.
8. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in "Dear doctor" letters and in black box labels. Clin Pharmacol Ther. 2002;72(6):735-742.
9. Cluxton RJ, Jr., Li Z, Heaton PC, et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiology Drug Safety. 2005;14(1): 1-9.
10. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiology Drug Safety. 2003;12(4):295-3.
11. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000;284(23):3036-3039.
12. Standards and Guidelines for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree, Accreditation Council for Pharmacy Education. www.acpe-accredit.org/pdf/ACPE_Revised_PharmD_Standards_Adopted_Jan152006.pdf. Accessed January 12, 2010.